Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer

Open access
Cooperberg, Matthew R., Cowan, Janet E., Hilton, Joan F., Reese, Adam C., Zaid, Harras B., Porten, Sima P., Shinohara, Katsuto, Meng, Maxwell V., Greene, Kirsten L., Carroll, Peter R.·2011·Journal of Clinical Oncology

Abstract

Purpose: Active surveillance (AS) is an option for the initial management of early-stage prostate cancer. Current risk stratification schema identify patients with low-risk disease who are presumed to be most suitable for AS. However, some men with higher risk disease also elect AS; outcomes for such men have not been widely reported. Patients and Methods: Men managed with AS at University of California, San Francisco, were classified as low- or intermediate-risk based on serum prostate-specific antigen (PSA), Gleason grade, extent of biopsy involvement, and T stage. Clinical and demographic characteristics, and progression in terms of Gleason score, PSA kinetics, and active treatment were compared between men with low- and intermediate-risk tumors. Results: Compared to men with low-risk tumors, those with intermediate-risk tumors were older (mean, 64.9 v 62.3 years) with higher mean PSA values (10.9 v 5.1 ng/mL), and more tumor involvement (mean, 20.4% v 15.3% positive biopsy cores; all P < .01). Within 4 years of the first positive biopsy, the clinical risk group did not differ in terms of the proportions experiencing progression-free survival, (low [54%] v intermediate [61%]; log-rank P = .22) or the proportions who underwent active treatment (low [30%] v intermediate [35%]; log-rank P = .88). Among men undergoing surgery, none were node positive and none had biochemical recurrence within 3 years. Conclusion: Selected men with intermediate-risk features be appropriate candidates for AS, and are not necessarily more likely to progress. AS for these men may provide an opportunity to further reduce overtreatment of disease that is unlikely to progress to advanced cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.31.4252

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 283

Metadata

Authors
Cooperberg, M. R., Cowan, J. E., Hilton, J. F., Reese, A. C., Zaid, H. B., Porten, S. P., Shinohara, K., Meng, M. V., Greene, K. L., & Carroll, P. R.
Venue
Journal of Clinical Oncology
Published
2011-01-10
Volume
29
Issue
2
Pages
228-234
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2141198296
Cited by
283
References
24
FWCI
17.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2010.31.4252
The paper
Cooperberg, M. R., Cowan, J. E., Hilton, J. F., Reese, A. C., Zaid, H. B., Porten, S. P., Shinohara, K., Meng, M. V., Greene, K. L., & Carroll, P. R. (2011). Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.31.4252

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.